Intelligent Ultrasound Group PLC Exercise of warrants and total voting rights (1920F)
2021年7月14日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMIUG
RNS Number : 1920F
Intelligent Ultrasound Group PLC
14 July 2021
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")
Exercise of Warrants
Total Voting Rights
Intelligent Ultrasound Group plc (AIM: IUG), the artificial
intelligence software and simulation company, announces that
pursuant to a receipt of notice for the exercise of warrants, it is
issuing 1,256,693 new ordinary shares with a nominal value of
GBP0.01 each at a subscription price of GBP0.01 per ordinary share.
The Company has received gross proceeds of GBP12,566.93.
The shares will rank pari passu with the existing ordinary
shares. Application has been made for the shares to be admitted to
trading on AIM ("Admission"), with Admission expected to occur on
19 July 2021.
Following Admission of the Shares, the Company will have
270,653,485 ordinary shares with a nominal value of GBP0.01 each in
issue with voting rights and admitted to trading on AIM. This
figure may then be used by shareholders in the Company as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules .
Enquiries:
Intelligent Ultrasound Group www. intelligentultrasound.com
plc
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cenkos Securities - Nominated Advisor Tel: +44 (0)20 7397 8900
and Broker
Giles Balleny / Max Gould (Corporate
Finance)
Dale Bellis / Julian Morse (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / Mob: +44
(0)7980 541 893
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) develops artificial
intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market and hi-fidelity virtual
reality simulators for the ultrasound training market. Based in
Cardiff in the UK and Atlanta in the US, the Group operates two
divisions:
Clinical AI Division
Focusses on developing deep learning-based algorithms to make
ultrasound machines smarter and more accessible. Products in the
market include :
ScanNav Assist
ScanNav Assist uses machine-learning based algorithms to
automatically identify and grade ultrasound images. GE Healthcare's
SonoLyst software on their Voluson SWIFT ultrasound machine
incorporates the ScanNav Assist AI technology and has received
510(k) clearance from the FDA for sale in the USA. SonoLyst is the
world's first fully integrated AI tool that recognises the 20 views
recommended by the International Society of Ultrasound in
Obstetrics and Gynaecology mid-trimester practice guidelines for
fetal imaging.
ScanNav Anatomy
ScanNav Anatomy Peripheral Nerve Block (PNB) uses
machine-learning based algorithms to simplify ultrasound-guided
needling by providing the user with real-time AI-based anatomy
highlighting software for a range of medical procedures. ScanNav
Anatomy has received CE approval and has also been submitted for
FDA regulatory approval.
ScanNav Anatomy PNB is therefore not available for sale in the
US or any other territory requiring government approval for this
type of product.
Simulation Division
Focusses on hi-fidelity ultrasound education and training
through simulation. Its main products are the ScanTrainer OBGYN
training simulator, the HeartWorks echocardiography training
simulator, the BodyWorks Eve Point of Care and Emergency Medicine
training simulator with Covid module and the new AI-based Anatomy
PNB training simulator. To date over 1,000 simulators have been
sold to over 600 medical institutions around the world.
www.intelligentultrasound.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFIFEEDDISLIL
(END) Dow Jones Newswires
July 14, 2021 02:00 ET (06:00 GMT)
Intelligent Ultrasound (LSE:MED)
過去 株価チャート
から 12 2024 まで 1 2025
Intelligent Ultrasound (LSE:MED)
過去 株価チャート
から 1 2024 まで 1 2025